How can we ensure that medicines originating in Dutch public institutions are affordable and accessible to all?

The high price of new medicines is often attributed to the cost of early stage research and development (R&D), which allegedly requires huge financial investment. However, the basic research on which drug development is built often originates in public institutions or is funded by government grants.

The Netherlands has been a pioneer in addressing the shortcomings of the current R&D model and exploring possible alternative innovation mechanisms. Yet, research originating in Dutch public research institutions has been used to develop medicines with huge price tags.

Health Action International, Wemos and Utrecht University will hold an event to bring together representatives from government and academia to discuss latest reports and tools on the issue, and how to ensure the guidelines they contain are made operational and embraced by all stakeholders for the benefit of patients. Following the panel discussion there will be a Q&A session with the audience.

Speakers and Panelists

  • Prof. Dr. Frank Miedema | Chair NFU Social Responsible Licensing Principles Working Group, UMCU
  • Ella Weggen | Senior Global Health Advocate at Wemos
  • Jaume Vidal | Senior Policy Advisor at Health Action International
  • Dr. Andre Broekmans | Board Member Utrecht Centre for Affordable Biotherapeutics
  • Dr. Jennifer Sellin | Assistant Professor at Department of International and European Law, Maastricht University (TBC)
  • Victoria Defelippe | President at Universities Allied for Essential Medicines the Netherlands (UAEM NL)

Moderators: Prof. Dr. Aukje Mantel-Teeuwisse and Prof. Dr. Bert Leufkens | Utrecht University

Source: Wemos communication
Registration: here